Annals of internal medicine

• Latest
• Best
• Search…

• Ann. Intern. Med. · Jan 2021

  In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.

  RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.

  keep reading… mark as read…

• Ann. Intern. Med. · Jan 2021

  Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study.

  Risk factors for progression of coronavirus disease 2019 (COVID-19) to severe disease or death are underexplored in U.S. cohorts. ⋯ Hopkins inHealth and COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response.

  read more… or not…

• Ann. Intern. Med. · Jan 2021

  Comment

  Newly prescribed canagliflozin vs. GLP-1 agonists was linked to amputation in older adults with type 2 DM and CVD.

  Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. 32843476.

  expand abstract… or not…

• Ann. Intern. Med. · Jan 2021

  Comment

  In adults with hypertension, more- vs. less-intensive BP-lowering treatment reduces orthostatic hypotension.

  Juraschek SP, Hu JR, Cluett JL, et al. Effects of intensive blood pressure treatment on orthostatic hypotension: a systematic review and individual participant-based meta-analysis. Ann Intern Med. 2020. [Epub ahead of print.] 32909814.

  explore more… or not…

• Ann. Intern. Med. · Jan 2021

  WHO recommends corticosteroids for patients with severe or critical COVID-19.

  Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. 32887691.

  expand abstract… or not…